2. NF-κB Metabolic Enzyme/Protease Immunology/Inflammation
  3. Keap1-Nrf2 Reactive Oxygen Species
  4. Chebulic acid

Chebulic acid is a phenolic acid compound isolated from Terminalia chebula with strong antioxidant activity, which breaks protein cross-links induced by advanced glycation end products (AGEs) and inhibits the formation of AGEs. Chebulic acid is effective in controlling elevated metabolic parameters, oxidative stress, and liver damage, supporting its beneficial role in asthma, diabetes, and liver protection.

For research use only. We do not sell to patients.

Chebulic acid Chemical Structure

Chebulic acid Chemical Structure

CAS No. : 23725-05-5

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 385 In-stock
Solution
10 mM * 1 mL in DMSO USD 385 In-stock
Solid
1 mg USD 150 In-stock
5 mg USD 350 In-stock
10 mg USD 550 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Chebulic acid Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Chebulic acid

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Chebulic acid is a phenolic acid compound isolated from Terminalia chebula with strong antioxidant activity, which breaks protein cross-links induced by advanced glycation end products (AGEs) and inhibits the formation of AGEs. Chebulic acid is effective in controlling elevated metabolic parameters, oxidative stress, and liver damage, supporting its beneficial role in asthma, diabetes, and liver protection[1][2][3][4][5].

In Vitro

Chebulic acid (0.5, 1, 5 and 10 μg/mL; 24 h) reduces UPM-induced ROS generation in NCI-H441 at doses of 5 and 10 μg/mL[1].
Chebulic acid (5 and 10 μM; 24 h) dose-dependently reduces the expression levels of inflammatory factors in NCIH441 and dose-dependently increases the mRNA expression levels of Occludin and ZO-1 proteins in NCI-H441 in the presence of UPM[1].
Chebulic acid (0-250 μM; 24 h) has a mild toxic effect on HUVEC at doses above 50 μM[3].
Chebulic acid (0, 5, 10 and 25 μM; 24 h) dose-dependently reduces glycer-AGEs-induced ROS generation in HUVECs and THP-1 monocyte adhesion, and dose-dependently promotes the restoration of TER in HUVECs at doses of 10 and 25 μM[3].
Chebulic acid (1, 10 and 100 μg/mL; 30 min) protectes hepatocytes from the cytotoxicity of t-BHP in a dose-dependent manner[4].
Chebulic acid (0-26 μM; 24 h) increases the expression of Nrf2 in the nucleus of L-02 cells in a dose-dependent and time-dependent manner, and increases the phosphorylation levels of ERK, JNK and p38 MARK[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chebulic acid Related Antibodies

Cell Viability Assay[4]

Cell Line: hepatocytes
Concentration: 1, 10 和 100 μg/mL
Incubation Time: 30 min
Result: Caused LDH leakage and MDA formation in t-BHP-treated cells, and decreased intracellular ROS levels in a dose-dependent manner. Caused t-BHP-treated cells to show cell viability similar to that of the control group at a dose of 100 μg/ml.
In Vivo

Chebulic acid (37.5, 75 and 150 mg/kg; p.o.; once daily for 5 days) is non-toxic to the liver of male ICR mice, protects against CCL4-induced liver injury through Nrf2 signaling and reduces serum ALT and AST levels and liver injury levels, including reduces necrosis and histological improvement[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Wistar albino rats of ischemia-reperfusion model[1].
Dosage: 25, 50 mg/kg
Administration: Oral gavage (p.o.) once a day for 28 days
Result: Reduced blood glucose, creatinine, urea nitrogen, glycated hemoglobin, proteinuria, urinary albumin excretion, glomerular filtration rate (GFR), and increased serum insulin and glycogen levels in diabetic rats.
Molecular Weight

356.24

Formula

C14H12O11
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C(O)[C@H]([C@@H](C1=C(O)C(O)=C(O)C=C12)[C@@H](C(O)=O)OC2=O)CC(O)=O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 125 mg/mL (350.89 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.8071 mL 14.0355 mL 28.0710 mL
5 mM 0.5614 mL 2.8071 mL 5.6142 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.17 mg/mL (6.09 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.17 mg/mL (6.09 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.91%

COA (258 KB) HNMR (267 KB) LCMS (84 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.8071 mL 14.0355 mL 28.0710 mL 70.1774 mL
5 mM 0.5614 mL 2.8071 mL 5.6142 mL 14.0355 mL
10 mM 0.2807 mL 1.4035 mL 2.8071 mL 7.0177 mL
15 mM 0.1871 mL 0.9357 mL 1.8714 mL 4.6785 mL
20 mM 0.1404 mL 0.7018 mL 1.4035 mL 3.5089 mL
25 mM 0.1123 mL 0.5614 mL 1.1228 mL 2.8071 mL
30 mM 0.0936 mL 0.4678 mL 0.9357 mL 2.3392 mL
40 mM 0.0702 mL 0.3509 mL 0.7018 mL 1.7544 mL
50 mM 0.0561 mL 0.2807 mL 0.5614 mL 1.4035 mL
60 mM 0.0468 mL 0.2339 mL 0.4678 mL 1.1696 mL
80 mM 0.0351 mL 0.1754 mL 0.3509 mL 0.8772 mL
100 mM 0.0281 mL 0.1404 mL 0.2807 mL 0.7018 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Chebulic acid Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Chebulic acid23725-05-5Keap1-Nrf2Reactive Oxygen SpeciesAntioxidant activityProtein cross-linkingasthmaNCI-H441HUVECL-02Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Chebulic acid
Cat. No.:
HY-N4170
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.